Arthritis Treatment
Administration of a monoclonal Ab (mAb) that specifically targets IL-1α is useful to treating articular and extra-articular symptoms of arthritis.
1 . A method for treating pain associated with arthritis in a human subject, the method comprising:
providing a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an anti-IL-1α antibody, and administering the pharmaceutical composition to the subject in an amount effective to reduce the pain associated with arthritis in the subject, wherein the pain is reduced.
2 . The method of claim 1 , wherein the pain occurs in a joint of the subject.
3 . The method of claim 1 , wherein the pain is in the uvea of the subject.
4 . The method of claim 1 , wherein the anti-IL-1α antibody is a monoclonal antibody.
5 . The method of claim 1 , wherein the anti-IL-1α antibody is a monoclonal antibody that comprises the all of the CDRs of MABp1.
6 . The method of claim 1 , wherein the antibody is MABp1.
7 . The method of claim 2 , wherein the pharmaceutical composition is administered by subcutaneous injection.
8 . The method of claim 3 , wherein the pharmaceutical composition is administered to the eye topically.
9 . The method of claim 1 , wherein the amount of the anti-IL-1α antibody effective to reduce pain associated with arthritis in the subject is sufficient to raise the subject's peripheral blood concentration of anti-IL-1α antibody to at least 4 micrograms/ml.
10 . The method of claim 1 , wherein the amount of the anti-IL-1α antibody effective to reduce pain associated with arthritis in the subject is sufficient to raise monocyte vacuolization in the subject.
11 . The method of claim 2 , wherein the mobility of the joint is improved after administration of the pharmaceutical composition.
12 . The method of claim 2 , wherein the pharmaceutical composition is administered to the subject after an injection of corticosteroid failed to relieve the pain.
13 . The method of claim 1 , wherein the subject lacked detectable endogenous anti-IL-la antibodies before administration of the pharmaceutical composition.
14 . The method of claim 1 , wherein the pharmaceutical composition is repeatedly administered to the subject until the pain is completely resolved.